Martin Diggle was appointed to Oxford BioMedica’s Board in October 2012. He is a founder of Vulpes Investment Management, which manages a number of funds including the Vulpes Life Sciences Fund -Oxford BioMedica’s largest shareholder. He has over 30 years’ experience in investment banking and fund management, and has been an investor in life sciences and biotech for nearly 20 years. He is also an expert in emerging markets and Russia, in particular, where he was previously a partner and director of UBS Brunswick. He holds a Master’s Degree in Philosophy, Politics and Economics from University of Oxford.